The use and popularity of GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound in weight loss and diabetes treatment have been on the rise. However, concerns have been raised about the full disclosure of risks and the impact on gender dynamics in obesity care. Influencers and telehealth marketers are promoting these drugs, but questions remain about the potential health risks associated with them.
Partisan Politics Returns To US FDA Congressional Oversight https://t.co/ZXzTonOoTi #PinkSheet
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows https://t.co/bMFGESbLTb #PinkSheet
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development https://t.co/iPwwnKmiOi #PinkSheet
Influencers Love Ozempic—but They Aren’t Telling You About the Risks (WSJ) Ask OpenEvidence: What are health risks associated with GLP-1 receptor agonists like Ozempic and Mounjaro?
American College Of Physicians Officially Recommends GLP-1s Like Ozempic For Diabetes Treatment—Despite Shortage Concerns https://t.co/Z8HMsoPnEP https://t.co/ZU8h0Aq6VP
Ozempic, Wegovy, Mounjaro and Zepbound are the first medicines to become social-media sensations. But the friends and influencers talking up the drugs aren’t always giving the full story. https://t.co/Ds4JUdSk7M https://t.co/Ds4JUdSk7M
Will Ozempic, Wegovy, Mounjaro, and Zepbound have an effect on the #gender dynamics of #ObesityCare? Some telehealth marketers want to give it a shot. https://t.co/DGqUOvoMlw
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing https://t.co/sK8nHBBFW4 #PinkSheet
💉Ozempic patients claim weight-loss jab has improved their fertility https://t.co/SCIXXM0Z3H
This week on "The Readout LOUD" podcast: How does a startup compete in the rapidly evolving field of weight loss drugs? And how did a major telemedicine company fall flat? https://t.co/b0EvO1NsCT
Perspective: Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists https://t.co/hb6SKJv6jh #HealthPolicy https://t.co/Q8l2vMe0Ax